Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
MILWAUKEE, WI / ACCESSWIRE / March 10, 2022 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is open for enrollment....
Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI), discusses its most successful year on record. - Increases technology platform and expects record revenues - Rolls out Phase I...
IB Zero G™ Technology May Benefit Imaging in Pediatric Patients MILWAUKEE, WI / ACCESSWIRE / November 11, 2021 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI), a developer of medical image processing platforms...
Installation Includes IB Neuro™ and IB DCE™ Software Purchase also Includes IB Clinic - Mac Edition MILWAUKEE, WI / ACCESSWIRE / November 2, 2021 / IQ-AI Limited (LSE:IQAI)(OTCQB:IQAIF), a developer...
Company Enjoys Most Successful Year on Record Marked Increase in Revenue and Growing Technology Portfolio Sponsorship of a Phase I Clinical Trial MILWAUKEE, WI / ACCESSWIRE / October 28, 2021 / IQ-AI Limited...